Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85)
| Autor: | R Schwan, Carlo Albera, L Romero Acuña, C Galvez, M.T. Santarelli, F Sousa Martínez, M Viniegra, Blajman C, G Chiessa, Bader M, R. Chacon, J. Nadal, Bruno M, A Romero |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Cyclophosphamide medicine.medical_treatment Breast Neoplasms Gastroenterology Breast cancer Statistical significance Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Neoplasm Staging Gynecology Chemotherapy business.industry Middle Aged medicine.disease Postmenopause Survival Rate Regimen Oncology Fluorouracil Chemotherapy Adjuvant Lymphatic Metastasis Female business medicine.drug Epirubicin Research Article |
| Zdroj: | British Journal of Cancer |
| ISSN: | 0007-0920 |
| Popis: | A randomized trial to compare adjuvant treatment with an alternating regimen with conventional chemotherapy was performed. A total of 589 node-positive patients were included and stratified according to number of positive nodes (N1-3 and N > 4) and menopausal status. Premenopausal N1-3 patients were randomized to cyclophosphamide, methotrexate and fluorouracil (CMF) or CMF/4'-epirubicin, cyclophosphamide (EC), post-menopausal N1-3 patients to fluorouracil, 4 epirubicin, cyclophosphamide (FEC) or CMF/EC and pre- and post-menopausal patients with N > or = 4 to fluorouracil, 4' epirubicin, cyclophosphamide, methotrexate, prednisone (FECMP) or CMF/EC. In premenopausal patients, CMF was superior to CMF/EC in terms of disease-free survival (DFS) (65% vs 45%, P = 0.0149) and survival (72.3% vs 50.2%, P = 0.0220) whereas, for N > or = 4 patients, differences between FECMP and CMF/EC did not achieve statistical significance (DFS 35% vs 26.2%; survival 50% vs 38.1%, P = NS). For post-menopausal patients, FEC was superior to CMF/EC in DFS (58.6% vs 36.8%, P = 0.0215) and survival (66.2% vs 46%, P = 0.0155). In post-menopausal patients with N > 4, differences favouring CMF/EC were significant in DFS (40.4% vs 22%, P = 0.0371) but not in survival (47.4% vs 32.2%, P = 0.1185). Alternating regimens did not offer better results in premenopausal and post-menopausal N1-3 patients. Results regarding post-menopausal N > 4 women require further confirmation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|